Your browser is no longer supported. Please, upgrade your browser.
Brooklyn ImmunoTherapeutics, Inc.
Index- P/E- EPS (ttm)-3.04 Insider Own0.50% Shs Outstand1.48M Perf Week-2.78%
Market Cap254.92M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float- Perf Month13.76%
Income-4.40M PEG- EPS next Q- Inst Own0.20% Short Float- Perf Quarter60.88%
Sales5.80M P/S43.95 EPS this Y-110.90% Inst Trans-70.04% Short Ratio0.04 Perf Half Y66.45%
Book/sh0.58 P/B13.26 EPS next Y- ROA-66.60% Target Price- Perf Year217.77%
Cash/sh0.02 P/C318.65 EPS next 5Y- ROE-248.90% 52W Range1.88 - 15.52 Perf YTD71.65%
Dividend- P/FCF- EPS past 5Y17.40% ROI-217.30% 52W High-50.45% Beta0.58
Dividend %- Quick Ratio0.70 Sales past 5Y-25.00% Gross Margin49.90% 52W Low309.04% ATR1.30
Employees22 Current Ratio0.70 Sales Q/Q-76.90% Oper. Margin- RSI (14)57.13 Volatility20.21% 19.34%
OptionableNo Debt/Eq2.22 EPS Q/Q122.50% Profit Margin-76.40% Rel Volume0.32 Prev Close7.94
ShortableNo LT Debt/Eq0.56 Earnings- Payout- Avg Volume1.86M Price7.69
Recom- SMA2036.38% SMA505.57% SMA20050.42% Volume588,733 Change-3.15%
Apr-19-21 04:10PM  
Apr-15-21 04:10PM  
Apr-06-21 08:00AM  
Mar-25-21 05:20PM  
Dec-14-20 08:44AM  
Nov-04-20 06:05PM  
May-08-20 10:37PM  
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.